Lipocine's Stock Plummets 78% Following Failed Phase 3 Trial for Oral Brexanolone

Lipocine Inc.'s stock dropped 78% after its Phase 3 trial for oral brexanolone to treat postpartum depression failed to meet its primary endpoint. The company plans to preserve capital and consult stakeholders to explore next steps.

• Lipocine's stock fell 78% after its Phase 3 trial for oral brexanolone failed to meet the primary endpoint.
• The trial evaluated LPCN 1154 for the treatment of postpartum depression.
• The stock is currently trading at $2.00, down from $9.25 in the previous close.
• Lipocine plans to preserve capital and consult stakeholders to explore future options.
• The company's stock has ranged between $2.01 and $12.37 over the past year.
• The failure underscores the risks of late-stage clinical trials in the biotech sector.